Pyridinium, 1,1'-[(6,13-dichloro-4,11-disulfo-3,10-triphenodioxazinediyl)bis[imino-2,1-ethanediylimino[6-[(2,5-disulfophenyl)amino]-1,3,5-triazine-4,2-diyl]]]bis[3-carboxy-, dihydroxide, bis(inner salt), hexasodium salt

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From March 07, 2016 to December 08, 2016

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Justification for type of information:

Note that this study was performed to meet non-European regulatory requirements and hence a positive control was included.
It is noted that positive controls should not be used for European evaluation.
The absence of a negative control was not a cause for concern in view of the negative outcome of the study.

Data source

Reference

Reference Type:

other company data

Title:

Unnamed

Year:

2016

Report date:

2016

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 406 (Skin Sensitisation)

GLP compliance:

yes

Type of study:

guinea pig maximisation test

Justification for non-LLNA method:

The guinea pig maximization test (GPMT) is already available for the registration outside of EU. Therefore, LLNA is not conducted.

Test material

Test material information

Constituent 1

Reference substance name:

Pyridinium, 1,1'-[(6,13-dichloro-4,11-disulfo-3,10-triphenodioxazinediyl)bis[imino-2,1-ethanediylimino[6-[(2,5-disulfophenyl)amino]-1,3,5-triazine-4,2-diyl]]]bis[3-carboxy-, dihydroxide, bis(inner salt), hexasodium salt

EC Number:

279-256-2

EC Name:

Pyridinium, 1,1'-[(6,13-dichloro-4,11-disulfo-3,10-triphenodioxazinediyl)bis[imino-2,1-ethanediylimino[6-[(2,5-disulfophenyl)amino]-1,3,5-triazine-4,2-diyl]]]bis[3-carboxy-, dihydroxide, bis(inner salt), hexasodium salt

Cas Number:

79771-28-1

Molecular formula:

C52H38Cl2N16O24S6.6Na

IUPAC Name:

Pyridinium, 1,1'-[(6,13-dichloro-4,11-disulfo-3,10-triphenodioxazinediyl)bis[imino-2,1-ethanediylimino[6-[(2,5-disulfophenyl)amino]-1,3,5-triazine-4,2-diyl]]]bis[3-carboxy-, dihydroxide, bis(inner salt), hexasodium salt

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Details on test material:

- Name of test material (as cited in study report): Everzol SB26
- Substance type: Powder
- Composition of test material, percentage of components: 78.12%
- Lot/batch No.: 3540
- Storage condition of test material: Ambient

In vivo test system

Test animals

Species:

guinea pig

Strain:

Hartley

Sex:

male

Details on test animals and environmental conditions:

- Source: WEI XIN HANG
- Weight at study initiation: 324.8-451.4g
- Housing: Every five animals were housed in a stainless steel wire mesh cage
- Acclimation period: 7 days
- Temperature (°C): 21 ± 2 °C
- Humidity (%): 55 ± 15%
- Photoperiod: 12-hrs dark / 12-hrs light

Study design: in vivo (non-LLNA)

Induction

Route:

intradermal and epicutaneous

Vehicle:

physiological saline

Concentration / amount:

0.1 mL and 0.5 mL of 10% Everzol SB26 for intradermal and epicutaneous, respectively

Day(s)/duration:

Day1 and Day7 for intradermal and epicutaneous, respectively

Adequacy of induction:

non-irritant substance, but skin pre-treated with 10% SDS

Challenge

Route:

epicutaneous, occlusive

Vehicle:

physiological saline

Concentration / amount:

0.5 mL of 10% Everzol SB26

Day(s)/duration:

Day23

Adequacy of challenge:

highest non-irritant concentration

No. of animals per dose:

For Control group: five
For Test group: ten

Positive control substance(s):

yes

Remarks:

α-Hexylcinnamaldehyde (HCA)

Results and discussion

Positive control results:

The latest results showed that positive control animals had shown skin reactions of 1-2 and the sensitization rate of α-Hexylcinnamaldehyde (HCA) was 100%.

In vivo (non-LLNA)

Results

Results 1

Reading:

1st reading

Hours after challenge:

48

Group:

negative control

Dose level:

10%

No. with + reactions:

0

Total no. in group:

5

Remarks on result:

no indication of skin sensitisation

Results 2

Reading:

1st reading

Hours after challenge:

48

Group:

test chemical

Dose level:

10% Everzol SB26

No. with + reactions:

0

Total no. in group:

10

Remarks on result:

no indication of skin sensitisation

Results 3

Reading:

1st reading

Hours after challenge:

48

Group:

positive control

Remarks on result:

not determinable

Any other information on results incl. tables

Table 1. The body weight of the guinea pigs

Group	Sex	Animal ID.	Animal Weight (g)		Weight Change (g)
			Day 1	Day 26
Control group	Male	71	390.3	502.7	+112.4
		72	332.3	428.3	+96.0
		73	324.8	397.2	+72.4
		74	390.6	503.0	+112.4
		75	352.2	456.5	+104.3
Test group	Male	76	408.9	513.9	+105.0
		77	407.7	494.5	+86.8
		78	368.4	461.6	+93.2
		79	422.1	517.0	+94.9
		80	438.1	542.3	+104.2
		81	411.1	518.2	+107.1
		82	407.7	511.3	+103.6
		83	338.6	434.5	+95.9
		84	451.4	544.2	+92.8
		85	405.8	510.6	+104.8

Table 2. Individual skin reaction of guinea pigs

Group	Sex	Animal ID.	Grade of skin reaction^1		Percent of Animals Sensitized	Sensitizing Capacity^2
			24 ± 1 hrs	48 ± 1 hrs
Control group	Male	71	0	0	0%	Weak
		72	0	0
		73	0	0
		74	0	0
		75	0	0
Test group	Male	76	0	0	0%	Weak
		77	0	0
		78	0	0
		79	0	0
		80	0	0
		81	0	0
		82	0	0
		83	0	0
		84	0	0
		85	0	0

¹ The skin reaction was grading according to “Magnusson and Kligman scale”.

² The sensitizing capacity of the test article was classified according to the “Scoring system of Kligman”.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

According to OECD 406 test method and “Scoring system of Kligman”, the sensitization rate of Everzol SB26 was 0% and Everzol SB26 caused no sensitization in guinea pigs. Therefore, Everzol SB26 was not met a category based on GHS criteria.

Executive summary:

This test using the procedures outlined in the SuperLab Study Plan for M62-151100130001EN which is based on the SOP for the OECD 406 (SOPP-339) and OECD 406 (OECD, 1992). The results of this OECD 406 test for Everzol SB26 show that test reliability criteria was met.

A 10% Everzol SB26 was used for intradermal injection and occlusively patched, to ten test guinea pigs to induce sensitization. The normal saline was used for similar injection and occlusively patched to five control guinea pigs. Following a recovery period, animals received a challenge patch with 10% Everzol SB26. The skin sensitization reactions were scored at approximately 24 and 48 hours after patch removal. At the end of study, body weight increase was observed in all animals. During 48 hours after challenge exposure, 0% treated animals showed sensitization to the Everzol SB26. Under the conditions of this study, Everzol SB26 did not caused any sensitization in guinea pigs.